Neurogene (NGNE) Common Equity (2013 - 2026)

Neurogene has reported Common Equity for 14 years, with the latest figure at $237.8 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 18.51% year-over-year to $237.8 million; the trailing twelve-month figure through Mar 2026 stood at $237.8 million (down 18.51% YoY), and the FY2025 full-year result was $264.9 million, down 14.66% from the prior year.
• Common Equity for Q1 2026 stood at $237.8 million, down from $264.9 million in the prior quarter.
• The five-year high for Common Equity was $310.4 million in Q4 2024, with the low at -$183.2 million in Q3 2023.
• Historically, Common Equity has averaged $117.0 million across 5 years, with a median of $155.0 million in 2024.
• The largest YoY upside for Common Equity was 227.64% in 2023 against a maximum downside of 273.42% in 2023.
• Neurogene's Common Equity stood at -$145.7 million in 2022, then soared by 227.64% to $186.0 million in 2023, then surged by 66.85% to $310.4 million in 2024, then dropped by 14.66% to $264.9 million in 2025, then fell by 10.23% to $237.8 million in 2026.
• The last three Common Equity figures came in at $237.8 million (Q1 2026), $264.9 million (Q4 2025), and $265.5 million (Q3 2025), per Business Quant data.